About Marinus Pharma
Marinus Pharma is a company based in Radnor (United States) founded in 2003 was acquired by Immedica in December 2024. Marinus Pharma has raised $71.58 million across 5 funding rounds from investors including Canaan, Immedica and Southern New Hampshire Health. Marinus Pharma offers products and services including Ganaxolone. Marinus Pharma operates in a competitive market with competitors including Arvelle Therapeutics, ORPHELIA Pharma, Corlieve Therapeutics, EpilepsyGTx and GenEp, among others.
- Headquarter Radnor, United States
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Marinus Pharmaceuticals, Inc.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Marinus Pharma
Marinus Pharma offers a comprehensive portfolio of products and services, including Ganaxolone.
Medication for treating severe epilepsy and seizure disorders.
People of Marinus Pharma
Unlock access to complete
Unlock access to complete
Funding Insights of Marinus Pharma
Marinus Pharma has successfully raised a total of $71.58M across 5 strategic funding rounds. The most recent funding activity was a Post-IPO round of $1.23 million completed in April 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Marinus Pharma
Marinus Pharma has secured backing from 7 investors, including venture fund and institutional investors. Prominent investors backing the company include Canaan, Immedica and Southern New Hampshire Health.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Canaan is recognized as an early-stage venture capital firm.
|
Locked | Locked | Locked | |
|
Biotech funding, drug development support, and investment in life sciences.
|
Locked | Locked | Locked | |
|
Healthcare investments are managed by corporate-backed venture capital fund RusnanoMedInvest.
|
Locked | Locked | Locked |
Investor details for Marinus Pharma
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Marinus Pharma
Investment portfolio details for Marinus Pharma
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Marinus Pharma
Detailed financials for Marinus Pharma
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Marinus Pharma Comparisons
Peer comparison for Marinus Pharma
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Marinus Pharma
Marinus Pharma operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Arvelle Therapeutics, ORPHELIA Pharma, Corlieve Therapeutics, EpilepsyGTx and GenEp, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Small molecule therapies are developed for partial-onset seizures treatment.
|
|
| Locked | Locked | Locked |
Therapies for pediatric neurology, oncology, and hematology are developed.
|
|
| Locked | Locked | Locked |
Therapeutics for neurological disorders are developed using AAV gene delivery.
|
|
| Locked | Locked | Locked |
Gene therapies for focal refractory epilepsy are developed.
|
|
| Locked | Locked | Locked |
Therapeutics for epilepsy are developed targeting ion channel mutations.
|
Detailed competitors of Marinus Pharma
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Marinus Pharma
Complete news archive for Marinus Pharma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Marinus Pharma
Marinus Pharma was founded in 2003 and raised its 1st funding round 2 years after it was founded.
Marinus Pharma is headquartered in Radnor, United States. It is registered at Radnor, Pennsylvania, United States.
Marinus Pharma is a funded company, having raised a total of $71.58M across 5 funding rounds to date.
Founded in 2003, Marinus Pharma is based in Radnor, United States, where pharmaceuticals targeting seizure disorders are developed. The lead product, Ganaxolone, is provided in intravenous and oral forms for addressing status epilepticus and rare orphan epilepsies. Operations encompass drug development within the neurology sector, alongside advocacy and associated initiatives.
Marinus Pharma's top competitors include Arvelle Therapeutics, ORPHELIA Pharma and Corlieve Therapeutics.
Marinus Pharma offers Ganaxolone.
Marinus Pharma has 7 investors. Key investors include Canaan, Immedica, Southern New Hampshire Health, Sofinnova, and RusnanoMedInvest.